Brought to you by 
Biocept nets $9.3mm through follow-on offering
12 Feb 2015
Executive Summary
Biocept Inc. (molecular diagnostics for cancer) netted $9.3mm through a follow-on public offering of 8mm common shares at $1.25. Investors also received five-year warrants to buy 8mm shares at $1.56. This was the first public stock sale for Biocept since its $17.7mm IPO a year ago.
Deal Industry
- In Vitro Diagnostics
- Laboratory Testing Services
- Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biocept nets $9.3mm through follow-on offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice